Latest Biotech News

C4X Discovery Holdings is set to receive a $13 million milestone payment from AstraZeneca after an oral NRF2 activator program entered the clinic. The trigger reflects AstraZeneca’s continued...

Rezubio Pharmaceuticals advanced RZ-520 for chronic respiratory diseases into Phase I after IND clearances from both the FDA and China’s NMPA, with dosing underway in healthy volunteers. In...

Superluminal Medicines raised an oversubscribed $60 million Series B to advance an AI-powered GPCR platform and to launch its first clinical trial by year-end. The financing, led by BVF Partners...

Merck and Moderna reported positive late-stage results for INTerpath-001, a Phase III trial evaluating Moderna’s bespoke mRNA therapeutic intismeran (mRNA-4157/V940) combined with Merck’s...

Novo Nordisk stopped two late-stage cardiovascular trials of ziltivekimab, its antibody targeting inflammation, after a data monitoring committee concluded the studies were unlikely to succeed....

Novartis reported that its Phase 3 pelacarsen program missed, adding to a run of cardiovascular outcomes trial failures across large-cap peers. The Swiss drugmaker said pelacarsen failed to show...

A San Raffaele Telethon Institute for Gene Therapy team evaluated liver-directed lentiviral vector gene therapy in a mouse model of methylmalonic acidemia and in patient-derived human fibroblasts....

Two separate cancer immunology advances highlighted how targeting immune regulatory circuits could translate into more effective tumor control. One study found that altered lncRNA profiles in NK...

Researchers at the University of Warwick, in collaboration with clinicians from University Hospital North Midlands NHS Trust and Imperial College London, used digital twin technology to evaluate a...

Novo Nordisk halted two late-stage cardiovascular trials of its IL-6 inhibitor ziltivekimab (HERMES and ATHENA) after an independent data monitoring committee determined the studies were unlikely...

Novartis reported that its Phase 3 pelacarsen trial missed its primary endpoint, adding another high-profile failure to the cardiovascular outcomes landscape. The result further challenges an...

Merck and Moderna reported positive Phase 3 results for INTerpath-001 (NCT05933577), testing their bespoke mRNA therapeutic intismeran (mRNA-4157/V940) in combination with Merck’s pembrolizumab...

Superluminal Medicines raised a $60 million oversubscribed Series B to advance its AI-powered GPCR platform and to initiate its first clinical trial by year-end. The round was led by BVF Partners,...

Researchers created fat tissue organoids that can recruit living T cells, generating a new in vitro model of immune–adipose cross-talk. The work, described in iScience, uses laboratory-grown fat...

A study in the Journal of Experimental & Clinical Cancer Research reported that stem-like survivors of targeted lung cancer therapy can be reprogrammed by neighboring mesenchymal stromal cells...

Acepodia obtained FDA IND clearance for ACE-723, a GPC3-targeted dual-payload antibody-drug conjugate aimed at unresectable or metastatic hepatocellular carcinoma. The company plans to begin a...

Researchers developed a “tumor-dressed” dendritic cell concept that combines expandable, genetically modifiable human induced pluripotent stem cells with tumor-membrane dressing to display...

A new study in Cancer Immunology, Immunotherapy reported that a bacterial metabolite circulating in patients colonized with carbapenem-resistant Klebsiella pneumoniae, 1,5-pentanediamine, can...

A preclinical Nature Aging study identified IL-11-driven ovarian extracellular matrix stiffening as a previously underappreciated driver of female reproductive aging. The authors reported that...

Merck and Moderna reported positive Phase III results for intismeran (mRNA-4157/V940), a bespoke, patient-specific mRNA-lipid nanoparticle therapeutic, in combination with pembrolizumab (Keytruda)...